Combination of PPAR-targeted therapies with other pharmacological agents in the treatment of NAFLD will warrant careful exploration, given the multi-systemic effects of PPAR modulation [217]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.